论文部分内容阅读
目的观察胰岛素联合吡格列酮治疗2型糖尿病的疗效。方法将64例单独应用胰岛素的2型糖尿病患者随机分成两组:胰岛素+吡格列酮组(治疗组)33例,胰岛素组(对照组)31例,观察12周。比较两组治疗前后的胰岛素用量、HbA1c、血脂、C肽、C反应蛋白(CRP)、体质量和低血糖次数等。结果治疗组胰岛素用量比对照组明显减少(P<0.05);HbA1c水平和低血糖发生次数均明显低于对照组(均P<0.05);TG和CRP较对照组和治疗前明显下降(P<0.05);两组间体质量差异无统计学意义(P>0.05)。结论胰岛素联合吡格列酮治疗能更有效地改善糖脂代谢,减少胰岛素用量及低血糖发生率,改善胰岛素抵抗。
Objective To observe the efficacy of insulin combined with pioglitazone in the treatment of type 2 diabetes mellitus. Methods Sixty-four insulin-deficient type 2 diabetic patients were randomly divided into two groups: insulin + pioglitazone group (treatment group), and insulin group (control group), 31 cases for 12 weeks. The levels of insulin, HbA1c, lipids, C-peptide, C-reactive protein (CRP), body weight and number of hypoglycemia in both groups before and after treatment were compared. Results The amount of insulin in the treatment group was significantly lower than that in the control group (P <0.05); the levels of HbA1c and hypoglycemia were significantly lower than those in the control group (all P <0.05); TG and CRP were significantly lower than those in the control group and before treatment (P < 0.05). There was no significant difference in body weight between the two groups (P> 0.05). Conclusion Insulin combined with pioglitazone treatment can more effectively improve glucose and lipid metabolism, reduce insulin dosage and incidence of hypoglycemia, improve insulin resistance.